Literature DB >> 23271577

Specific VpU codon changes were significantly associated with gp120 V3 tropic signatures in HIV-1 B-subtype.

Salvatore Dimonte1, Muhammed Babakir-Mina, Stefano Aquaro, Carlo-Federico Perno.   

Abstract

After infection and integration steps, HIV-1 transcriptions increase sharply and singly-spliced mRNAs are produced. These encode Env (gp120 and gp41) and auxiliary proteins Vif, Vpr and VpU. The same localization within the unique structure of the mRNAs suggests that the VpU sequence prior to the Env could affect the Env polyprotein expression.The HIV-1 infection process begins when the gp120 subunit of the envelope glycoprotein complex interacts with its receptor(s) on the target cell. The V3 domain of gp120 is the major determinant of cellular co-receptor binding. According to phenotypic information of HIV-1 isolates, sequences from the VpU to V3 regions (119 in R5- and 120 X4-tropic viruses; one per patient) were analysed. The binomial correlation phi coefficient was used to assess covariation among VpU and gp120(V3) signatures. Subsequently, average linkage hierarchical agglomerative clustering was performed. Beyond the classical V3 signatures (R5-viruses: S11, E25D; X4-viruses: S11KR, E25KRQ), other specific V3 and novel VpU signatures were found to be statistically associated with co-receptor usage. Several statistically significant associations between V3 and VpU mutations were also observed. The dendrogram showed two distinct large clusters: one associated with R5-tropic sequences (bootstrap=0.94), involving: (a) H13NP(V3), E25D(V3), S11(V3), T22A(V3) and Q61H(VpU), (b) E25A(V3) and L12F(VpU), (c) D44E(VpU), R18Q(V3) and D80N(VpU); and another associated with X4-tropic sequences (bootstrap=0.97), involving: (i) E25I(V3) and V10A(VpU), (ii) 0-1insV(VpU), H13R(V3), I46L(VpU), I30M(V3) and 60-62del(VpU), (iii) S11KR(V3) and E25KRQ(V3). Some of these pairs of mutations were encoded always by one specific codon. These data indicate the possible VpU mutational patterns contributing to regulation of HIV-1 tropism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271577      PMCID: PMC8218112          DOI: 10.1007/s12250-012-3287-0

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  43 in total

1.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors.

Authors:  K Fujita; S Omura; J Silver
Journal:  J Gen Virol       Date:  1997-03       Impact factor: 3.891

4.  Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques.

Authors:  Edward B Stephens; Coleen McCormick; Erik Pacyniak; Darcy Griffin; David M Pinson; Francis Sun; Warren Nothnick; Scott W Wong; Robert Gunderson; Nancy E J Berman; Dinesh K Singh
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

5.  A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine.

Authors:  David R Hout; Lisa M Gomez; Erik Pacyniak; Jean-Marie Miller; M Sarah Hill; Edward B Stephens
Journal:  Virology       Date:  2006-02-03       Impact factor: 3.616

6.  T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism.

Authors:  Nathalie Dejucq; Graham Simmons; Paul R Clapham
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

7.  Human immunodeficiency virus type 1 Vpu modifies viral cytopathic effect through augmented virus release.

Authors:  Y Iwatani; S K Song; L Wang; J Planas; H Sakai; A Ishimoto; M W Cloyd
Journal:  J Gen Virol       Date:  1997-04       Impact factor: 3.891

8.  Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes.

Authors:  U Schubert; K A Clouse; K Strebel
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

Review 9.  Modulation of HIV-1-host interaction: role of the Vpu accessory protein.

Authors:  Mathieu Dubé; Mariana G Bego; Catherine Paquay; Éric A Cohen
Journal:  Retrovirology       Date:  2010-12-22       Impact factor: 4.602

10.  Oligomerization of the human immunodeficiency virus type 1 (HIV-1) Vpu protein--a genetic, biochemical and biophysical analysis.

Authors:  Amjad Hussain; Suman R Das; Charu Tanwar; Shahid Jameel
Journal:  Virol J       Date:  2007-08-29       Impact factor: 4.099

View more
  2 in total

1.  HIV-1 B-subtype capsid protein: a characterization of amino acid's conservation and its significant association with integrase signatures.

Authors:  Salvatore Dimonte; Muhammed Babakir-Mina; Stefano Aquaro
Journal:  Virus Genes       Date:  2014-01-29       Impact factor: 2.332

2.  Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.

Authors:  S Dimonte; M Babakir-Mina; S Aquaro; C-F Perno
Journal:  Infection       Date:  2013-04-26       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.